All News
Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card.
We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better.
#ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW
David Liew drdavidliew ( View Tweet)
Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa
Richard Conway RichardPAConway ( View Tweet)
@US_FDA rheumatology approvals, 2025
#ACR25 @RheumNow https://t.co/uVLWqBx45m
David Liew drdavidliew ( View Tweet)
IgG4 - Rare but Rx
Several studies #ACR25 @ACRheum were presented
Outcome measures
Rx
#steroids
#CD19 mAb #Inebilizumab
👍+RCT reduction of flares
BTKi
#Rilzabrutinib
#Zanubrutinib
#JAKi
+RCT of #tofacitinib +steroids vs pred
@ACRheum @RheumNow #ACR25
1163 LB02 0239 1172 https://t.co/xC3wgaN9bk
Janet Pope Janetbirdope ( View Tweet)
Sjögren’s, decoded by Ab -->ESSDAI domains:
• anti-SSA → glandular
• anti-Ro52 / SCL70 → biologic activity
• anti-nucleosome → pulmonary
• anti-histone → pulmonary + cutaneous
Distinct serologic–ESSDAI patterns may guide monitoring and management
@RheumNow #ACR25 A#2295
Jiha Lee JihaRheum ( View Tweet)
#ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% sensitivity and 0.861 AUC. Supports biomarker-driven personalization of PsA treatment. Abstract#2371 @RheumNow #ACR25 https://t.co/lojQFfWsJi
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX
Richard Conway RichardPAConway ( View Tweet)
In RA, “strong bones” can give false reassurance.
Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline.
@RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9
Jiha Lee JihaRheum ( View Tweet)
After melanoma, should RA patients stop DMARDs?
These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs
Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma
#ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln
David Liew drdavidliew ( View Tweet)
#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too!
Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#IL2 #Rx in active #SLE?
Maybe 🤔
IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact.
RCT of IL2i in #SLE gave a good dose response and improved TRegs.
#ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We
Links:
Janet Pope Janetbirdope ( View Tweet)
Can a Fitbit track RA?
This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic.
Maybe instead of asking about our patients mobility and sleep, we should be measuring it?
#ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2
David Liew drdavidliew ( View Tweet)
#1751 In early RA, higher disease activity, inflammation & older age linked to more ILD changes on machine-learning chest CT. Even subtle QCT abnormalities correlated with reduced lung function pointing to early inflammatory pathways in RA-ILD. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Are the clues of RA there in the EMR, before the diagnosis is made?
Jina off-the-shelf AI with subsequent retraining found the digital fingerprint of RA in @MayoClinic medical notes, years before formal diagnosis.
The clues are there
#ACR25 ABST2260 @MyasoedovaElena @RheumNow https://t.co/onGlKUmefd
David Liew drdavidliew ( View Tweet)
Adverse events from avacopan the WHO pharmacovigilence database (VigiBase)
Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare
Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz
Mike Putman EBRheum ( View Tweet)
Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356 https://t.co/bImzTA7uUC
Richard Conway RichardPAConway ( View Tweet)
In a 4-year study of 85 SpA patients, ChatGPT-4o matched SPSS in analyzing NLR/PLR trends. Outputs were identical, but ChatGPT offered faster interpretation and clinical context, highlighting AI’s potential to streamline early-stage research. Abstract#2354 @RheumNow #ACR25 https://t.co/W3pPQijPBD
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In the CLOSE-UP study of UPA in RA
- 61% in remission with responses sustained to 24 mo
- Benefit consistent irrespective of prior DMARD use
- No new safety signals
@RheumNow #ACR25 Abstract#2281
Jiha Lee JihaRheum ( View Tweet)
Infection vs steroid sparing in PMR/GCA/AAV studies with steroid-sparing Rx
GiACTA (1, top right) aside,
- low infection rates
- the more steroid saved, the less the infection risk
Infection risk in vasculitis is driven by steroid, not DMARD
#ACR25 ABST2526 @RheumNow https://t.co/UprbxUQyQC
David Liew drdavidliew ( View Tweet)
